

Visit our new Pharmacy Corner at
www.zegerid.com/pharmacists

**Only ZEGERID provides
immediate release with
the POWER of continued
acid control —
Night and Day***



ZEGERID is unique: substitutions NOT allowed

- Only ZEGERID (omeprazole/sodium bicarbonate) is built for rapid and continued acid control¹
—ZEGERID contains omeprazole, a proton pump inhibitor (PPI), and sodium bicarbonate, an antacid
- ZEGERID is **not interchangeable** with Prilosec[®], Prilosec OTC[®], or generic omeprazole²
- No AB-rated generic equivalent** according to the FDA Orange Book²
- Delayed-release omeprazole products or formulations are **not therapeutically equivalent** to ZEGERID²
—All other oral PPIs are delayed release and require enteric coatings that delay absorption and initial acid suppression³⁻⁸

Order ZEGERID: Contact your wholesaler to order ZEGERID Capsules or ZEGERID Powder for Oral Suspension

NDC#	Unit Size
68012-104-30	40 mg capsules in a 30-count bottle
68012-102-30	20 mg capsules in a 30-count bottle
68012-054-30	40 mg powder for oral suspension in a 30-count box
68012-052-30	20 mg powder for oral suspension in a 30-count box

*Gastric pH >4 ranged from 12.2 to 18.6 hours on Day 7.¹

Prilosec and Prilosec OTC are registered trademarks of the AstraZeneca group of companies.



References: **1.** ZEGERID Prescribing Information. Santarus, Inc. April 2007. **2.** FDA Web site. Electronic Orange Book. Available at: <http://www.fda.gov/cder/ob/default.htm>. Accessed August 2007. **3.** Aciphex Prescribing Information. Eisai Inc. and Janssen Pharmaceutica Inc. August 2003. **4.** Nexium Prescribing Information. AstraZeneca. April 2007. **5.** Prevacid Prescribing Information. TAP Pharmaceutical Products Inc. June 2007. **6.** Prilosec Prescribing Information. AstraZeneca. September 2006. **7.** Protonix Prescribing Information. Wyeth Pharmaceuticals, Inc. June 2007. **8.** Castell D. Review of immediate-release omeprazole for the treatment of gastric acid-related disorders. *Expert Opin Pharmacother.* 2005;6:2501-2510. **9.** Castell D, Bagin R, Goldlust B, Major J, Hepburn B. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease. *Aliment Pharmacol Ther.* 2005;21:1467-1474. **10.** Katz PO, Koch FK, Ballard ED, et al. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms. *Aliment Pharmacol Ther.* 2007;25:197-205. **11.** Wolters Kluwer Health, Dynamic Claims, September 2006. Note: A portion of these approvals may be reversed by the patient. **12.** MediMedia Information Technologies. *Formulary Compass*[™]. November 2006.

First and Only Immediate-Release oral PPI

Zegerid[®]
omeprazole/sodium bicarbonate

No other oral PPI provides the combined benefits of ZEGERID

ZEGERID is the First and Only Immediate-Release oral PPI



- Achieves peak plasma levels in **~30 minutes**, so it may start working earlier than delayed-release oral PPIs^{1,3-8}
- Effectively controls acid during the nighttime hours^{9,10}
- Extensive managed care coverage, so you have the freedom to dispense the **ONLY** oral PPI with the benefits of rapid release and continued control — Night and Day^{11,12§}
- 40 mg dose provides **18.6 hours** (median) of continued acid control, maintaining gastric pH >4 throughout the night and day^{1*††}

The correlation of pharmacodynamic data to clinical effect has not been established

Product Description

ZEGERID® (omeprazole/sodium bicarbonate) contains omeprazole, a proton pump inhibitor (PPI), and sodium bicarbonate, an antacid, which raises the gastric pH and thus protects omeprazole from acid degradation.

Indications and Dosing for ZEGERID

ZEGERID is indicated for heartburn and other symptoms associated with gastroesophageal reflux disease (GERD) (20 mg QD); for the short-term treatment (4-8 weeks) of erosive esophagitis diagnosed by endoscopy (20 mg QD); for maintenance of healing of erosive esophagitis (20 mg QD) (controlled studies do not extend beyond 12 months); for short-term treatment (4-8 weeks) of active duodenal ulcer (20 mg QD); for short-term treatment (4-8 weeks) of active benign gastric ulcer (40 mg QD); and for reduction of risk of upper gastrointestinal bleeding in critically ill patients (only powder for oral suspension 40 mg/1680 mg QD; use beyond 14 days has not been evaluated).

Important Safety Information about ZEGERID

The most frequently reported adverse events with ZEGERID are headache, diarrhea, and abdominal pain. In critically ill patients treated with ZEGERID,

adverse events generally reflected the serious, underlying medical condition of the patients, and were similar for patients treated with ZEGERID and with the comparator (acid-controlling) drug. Symptomatic response to therapy does not preclude the presence of gastric malignancy. Atrophic gastritis has been noted occasionally in gastric corpus biopsies from patients treated long term with omeprazole.

ZEGERID Capsules contain 303 mg of sodium per dose. ZEGERID Powder for Oral Suspension contains 460 mg of sodium per dose. This should be taken into consideration for patients on a sodium-restricted diet.

Sodium bicarbonate is contraindicated in patients with metabolic alkalosis and hypocalcemia. ZEGERID is contraindicated in patients with known hypersensitivity to any component of the formulation.

Since both 20 mg and 40 mg ZEGERID contain the same amount of sodium bicarbonate (1100 mg in capsules, 1680 mg in packets of powder for oral suspension), two 20 mg capsules are not equivalent to, and should not be substituted for, one 40 mg capsule, and two 20 mg packets are not equivalent to, and should not be substituted for, one 40 mg packet.

Please see accompanying full Prescribing Information.

*This pharmacodynamic study measured the median percentage of time gastric pH >4 as 18.6 hours over 24 hours with ZEGERID 40 mg Powder for Oral Suspension in healthy subjects (n=24).

†Powder for oral suspension.

‡Median values for the time gastric pH >4 for patients taking ZEGERID Powder for Oral Suspension and Capsules, 20 mg and 40 mg doses, **ranged from 12.2 to 18.6 hours on Day 7.**

§The information provided is not a guarantee of coverage or payment (full or partial). Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures.



© 2007 Santarus, Inc. 1-ZEG07327 September 2007 Printed in the USA

First and Only Immediate-Release oral PPI

Zegerid®
omeprazole/sodium bicarbonate

Visit us at www.zegerid.com/pharmacists